PIK3CA and adenocarcinoma: Fifty-five consecutive patients with metastatic or recurrent adenocarcinoma (n = 24) or squamous cell carcinoma (n = 31) who had a test for PIK3CA mutation and/or PTEN loss/mutation and underwent treatment in at least one phase I clinical trial in the Phase I Clinical Trials Program were included in this study.